Overall and inter‐individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes
Primary result · Plasma suPAR changeResult — go to the resultDifference −19.7 % 95% CI −23.1 to −16.3Authors' conclusion
We demonstrated no overall effect of 4-week treatment with telmisartan, empagliflozin, linagliptin or baricitinib on suPAR. However, individualization of treatment might significantly reduce suPAR levels.
Study context
- Population
- Adults with T1D (26) or T2D (40) with urinary albumin-creatinine ratio ≥30 and ≤500 mg/g26 T1D, 40 T2D
- Comparison
- Telmisartan vs empagliflozin vs linagliptin vs baricitinib; individual best-performing drug vs mean of other three
- Primary endpoint
- Change in plasma suPAR after each treatment
- Follow-up
- 4 weeks
Methodological detailsopen-label, 4-week washouts, Repeated-measures linear mixed-effects models
- Open-label
- 4-week washouts
- Repeated-measures linear mixed-effects models
Primary result
Plasma suPAR change
Difference
−19.7 %
95% CI −23.1 to −16.3
P < 0.001
Individual best-performing drugvs Other three drugs (mean)
difference −19.7 % (95% CI −23.1 to −16.3); P < 0.001
As reported in the abstract
- Reduction in soluble urokinase plasminogen activator receptor (suPAR) with individual best-performing drug
- 13.3% (95% CI 3.7, 22.8; P = 0.007)
Further findings
Individual best-performing drug
Baseline plasma suPAR
- Baseline median (IQR) plasma suPAR
- 3.5 (2.9, 4.3) ng/mL
Original publication
Overall and inter‐individual effect of four different drug classes on soluble urokinase plasminogen activator receptor in type 1 and type 2 diabetes. Diabetes Obes Metab. Published 7 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →